ganfort has been researched along with Glaucoma--Neovascular* in 1 studies
1 other study(ies) available for ganfort and Glaucoma--Neovascular
Article | Year |
---|---|
The fixed combination efficacy assessment in patients with secondary neovascular glaucoma and diabetes mellitus.
To assess IOP-lowering efficacy of bimatoprost/timolol fixed combination (Ganfort®) in patients with diabetes mellitus (DM) and uncontrolled secondary neovascular glaucoma (NG).. Fifty patients (51 eyes) with uncontrolled secondary neovascular glaucoma and diabetes mellitus were enrolled in the study. All patients with an uncontrolled IOP have been proposed to switch current IOP-lowering therapy to Ganfort®. In case target IOP level was not reached filtration surgery was recommended. Ganfort® administration - once a day in the morning.. IOP-lowering has been observed in all patients when switched to Ganfort®. Mean IOP level was almost 3-x lower versus baseline in 72.5% of patients (37 eyes). The patients achieved target IOP of 15-17 mmHg. As a result, no surgical intervention was required. Significant IOP-lowering has been observed in another group of patients (14 eyes, 27.5 %) nevertheless due to glaucoma progression, these patients are still subjected to surgical treatment.. IOP-lowering fixed combination Ganfort® (Allergan) can be used in patients with secondary neovascular glaucoma and diabetes mellitus as a drug of choice to control the IOP level. Even in cases when target IOP is not achieved, Ganfort® can be administered in pre-operative period and helps to reduce postoperative complications. Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amides; Cloprostenol; Diabetic Angiopathies; Drug Combinations; Drug Substitution; Female; Glaucoma, Neovascular; Humans; Intraocular Pressure; Male; Middle Aged; Timolol; Treatment Outcome | 2015 |